Emergent Biosolutions Inc Stock Price, News & Analysis

Emergent BioSolutions (NYSE: EBS) has scheduled a conference call for November 8, 2022, at 5:00 PM ET to review its Q3 2022 financial results, recent business developments, and 2022 financial outlook. Investors can join via webcast or by phone after registering. A replay will be accessible on the company’s investor page. Emergent BioSolutions focuses on defending public health threats through vaccines and therapeutics and aims to enhance the lives of one billion people by 2030.

Emergent BioSolutions (NYSE: EBS) has successfully acquired exclusive worldwide rights to TEMBEXA® (brincidofovir) from Chimerix. The FDA-approved antiviral, indicated for smallpox treatment in all age groups, enhances Emergent's medical countermeasure portfolio. The acquisition follows regulatory approvals, including BARDA's consent for a $680 million contract covering up to 1.7 million treatment courses. Emergent's initial payment is $238 million, with additional milestone and royalty payments based on U.S. and international sales.

Emergent BioSolutions (NYSE: EBS) has commenced dosing the first participant in a Phase 1 clinical trial of EBS-LASV, a VSV-vectored vaccine aimed at combating Lassa virus infections. The study, co-funded by CEPI, will assess the vaccine's safety and immunogenicity in around 36 healthy adults in Ghana. Dr. Kelly Warfield emphasized the company's commitment to addressing public health threats, while CEPI highlighted the urgency of developing solutions against Lassa fever, which currently lacks approved vaccines or treatments.

Emergent BioSolutions (NYSE: EBS) announced participation in several investor conferences in August and September 2022. Key events include the 12th Annual Midwest IDEAS Investor Conference on August 24, a fireside chat at the Wells Fargo 2022 Healthcare Conference and Leveraged Finance Conference on September 8, and the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14. Webcast presentations will cover recent business developments and financial results, available live and on replay from the Emergent website.

Emergent BioSolutions (NYSE: EBS) reported Q2 2022 results with total revenues of $242.7 million, down 39% year-over-year. Net loss reached $56.4 million, marking a significant decline from the prior year's profit of $4.6 million. Adjusted EBITDA stood at $(28.8) million, down from $49.5 million. The company executed an agreement to acquire TEMBEXA and announced an FDA review of its anthrax vaccine. For 2022, total revenue guidance has been set at $1.15 to $1.25 billion, with CDMO revenues projected at $105 to $125 million.

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on August 1, 2022, at 5:00 PM ET to discuss its Q2 2022 financial results and provide revenue guidance for Q3 2022 and the full year. The call will cover recent business developments and financial outlook. Participants can join via webcast or telephone after registration. A replay will be available on Emergent's Investors page.

Emergent focuses on public health threats, developing vaccines and therapeutics, and offering contract development services.

Emergent BioSolutions (NYSE: EBS) has formed a collaboration with Ridgeback Biotherapeutics to enhance availability of Ebanga™ (Ansuvimab-zykl) for Ebola treatment. Emergent will manage manufacturing, sales, and distribution in the U.S. and Canada, while Ridgeback will ensure free access to patients in endemic regions through its compassionate use program. Ebanga™, FDA-approved since December 2020, is crucial for combating Ebola. The partnership emphasizes both companies' commitment to addressing public health threats and ensuring equitable access to life-saving treatments.

Emergent BioSolutions (NYSE:EBS) appointed Sujata Dayal as a Class II director, effective July 15, 2022, with her term expiring at the 2023 annual meeting. Dayal brings extensive experience in healthcare compliance, having previously served at Medline, Johnson & Johnson, Biomet, and Abbott Laboratories. As a new board member, she joins the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight, positioning her to significantly contribute to the company's growth and compliance efforts.

Emergent BioSolutions Inc. (NYSE:EBS) announced that the FDA has accepted for review its Biologics License Application (BLA) for AV7909, a new anthrax vaccine candidate for post-exposure prophylaxis in individuals aged 18-65. The Prescription Drug User Fee Act goal date for the FDA's decision is April 2023. This application is based on pivotal phase 3 clinical study data evaluating the vaccine's efficacy and safety. Emergent has collaborated with the U.S. government for over 20 years on this project, aiming to enhance public health preparedness against anthrax threats.